Table S3.
Treatment outcomes and response
| First-line chemotherapy | Second-line chemotherapy | Third-line chemotherapy | |
|---|---|---|---|
| N | 118 | 65 | 31 |
| Outcomes | |||
| Delivered courses (courses) | |||
| Mean ± standard deviation | 3.9±1.6 | 3.4±1.9 | 2.5±1.6 |
| Reasons of discontinuation (N) | |||
| Progressive disease | 31 | 41 | 18 |
| Completion of 4–6 courses | 54 | 13 | 2 |
| Adverse effects | 6 | 0 | 1 |
| Refused by patients | 9 | 3 | 3 |
| Cancer-related deteriorated condition | 2 | 3 | 5 |
| Comorbidity-related deteriorated condition | 14 | 5 | 2 |
| Ongoing | 2 | 0 | 0 |
| Response | |||
| CR (N) | 17 | 1 | 0 |
| PR (N) | 70 | 20 | 4 |
| SD (N) | 13 | 10 | 4 |
| PD (N) | 8 | 31 | 23 |
| NE (N) | 10 | 3 | 4 |
| ORR (%) | 73.7 | 32.3 | 12.9 |
| DCR (%) | 84.7 | 47.7 | 25.8 |
| PFS (days) | |||
| Median (95% CI) | 161 (140–181) | 103 (71–112) | 63 (39–82) |
Abbreviations: CI, confidence interval; CR, complete response; DCR, disease control rate; NE, not evaluated; ORR, overall response rate; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.